Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association
The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice. First, the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America HF guidelines provided recommendations, for the first time, on the clinical utility of multivariable risk equations to estimate risk of incident HF. Second, the American Heart Association recently developed the PREVENT (Predicting Risk of Cardiovascular Disease Events) equations, which not only enable prediction of incident HF separately, but also include HF in the prediction of total cardiovascular disease. Third, the predominant phenotype of HF risk has emerged as the cardiovascular-kidney-metabolic syndrome. Fourth, the emergence of novel therapies that prevent incident HF (eg, sodium-glucose cotransporter-2 inhibitors) and target multiple cardiovascular-kidney-metabolic axes demonstrate growing potential for risk-based interventions. Whereas the concept of risk-based prevention has been established for decades, it has only been operationalized for atherosclerotic cardiovascular disease prevention to date. Translating these opportunities into a conceptual framework of risk-based primary prevention of HF requires implementation of PREVENT-HF (Predicting Risk of Cardiovascular Disease Events–Heart Failure) equations, targeted use of cardiac biomarkers (eg, natriuretic peptides) and echocardiography for risk reclassification and earlier detection of pre-HF, and definition of therapy-specific risk thresholds that incorporate net benefit and cost-effectiveness. This scientific statement reviews the current evidence for accurate risk prediction, defines strategies for equitable prevention, and proposes potential strategies for the successful implementation of risk-based primary prevention of HF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While waist-hip ratio provides improved characterization of metabolic and cardiovascular risk than waist circumference, challenges of complexity of measurement and lack of standardization make it less ideal for use in clinical settings.18,29–32”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [32]
In the citing paper
“Using both BMI and waist circumference provides complementary prognostic information regarding risk for future metabolic derangements, incident CVD, and mortality.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [32]
In the citing paper
“A Scientific Statement describes the extent to which popular diets align with AHA dietary guidance, with the Dietary Approaches to Stop Hypertension (DASH), Mediterranean, pescatarian, and vegetarian dietary patterns providing particularly notable cardiometabolic benefits by reducing the risks of hypertension, T2D, and CVD.32”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [32]
In the citing paper
“Cohort studies and interventional trials have provided evidence for the weight, glycemic, and metabolic benefits of lifestyle modification, including regular physical activity and a balanced diet, in those with T2D.30–32”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [32]
In the citing paper
“Clinical trials of the nsMRA finerenone in patients with CKD, T2D, and albuminuria despite RASi, as well as eGFR ≥25 mL/min/1.73 m2, have shown significant kidney and cardiovascular benefits of finerenone.11,12,30–32”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [32]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247 · cited 1×
“In contrast, there is concern that dipeptidyl peptidase-4 inhibitors and some thiazolidinediones may exacerbate risk of HF. 103–108 The emergence of SGLT2is offers a potential promising strategy for HF prevention, and RCTs have consistently demonstrated lowering of the risk of incident HF across a…”
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Cited by
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 151
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Self-citationPrioritising the primary prevention of heart failure
Khan, S. S., Berwanger, O. B., Fiuzat, M., McMurray, J. J. V., Narula, J., Prabhakaran, D., Sliwa, K. S., Tromp, J., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01393-5 · Cited by 90
Self-citationÖzyüncü, N., & Erol, Ç. (2025) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2025.5602 · Cited by 22
Khan, S. S., Abdalla, M., Bello, N. A., Blyler, C. A., Carter, J., Commodore-Mensah, Y. Y., Ferdinand, K. C., Johnson, H. M., Jones, D. W., Khera, A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000248 · Cited by 18
Self-citation
Metadata
- Authors
- Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., & on behalf of the American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; Council on Cardiovascular and Stroke Nursing; Council on Basic Cardiovascular Sciences; Council on Clinical Cardiology; Council on Hypertension; and Council on Quality of Care and Outcomes Research
- ORCID
- Venue
- Circulation
- Published
- 2025-05-20
- Volume
- 151
- Issue
- 20
- Pages
- e1006-e1026
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4409482288
- Semantic Scholar
- cdcd0586e097b2be55caf47be535bed5e2bc1c15
- Cited by
- 75
- References
- 160
- Citations by year
- 2026: 49 · 2025: 26
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- heart failure, primary prevention, risk-based prevention, risk prediction, PREVENT equations, cardiovascular-kidney-metabolic syndrome, SGLT2 inhibitors, natriuretic peptides, echocardiography, risk reclassification, net benefit, cost-effectiveness, risk thresholds
- MeSH terms
- Heart Disease Risk Factors, American Heart Association, Heart Failure, Humans, Primary Prevention, Risk Factors, United States, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association. https://app.cochat.ai/papers/10.1161/cir.0000000000001307
- The paper
- Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., & on behalf of the American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; Council on Cardiovascular and Stroke Nursing; Council on Basic Cardiovascular Sciences; Council on Clinical Cardiology; Council on Hypertension; and Council on Quality of Care and Outcomes Research. (2025). Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. https://doi.org/10.1161/cir.0000000000001307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.